Skip Navigation

European Heart Journal 1994 15(2):242-246;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by JONDEAU, G.
Right arrow Articles by DUMAS, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JONDEAU, G.
Right arrow Articles by DUMAS, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Oral enoximone as a substitute for infravenous catecholamine support in end-stage congestive heart failure

G. JONDEAU*,, O. DUBOURG*, G. DELORME*, J. F. ARNAL*, F. CHIKLI*, L. KAMOUN*, C. DUMAS{dagger} and J. P. DUMAS*

*Hôpital A Paré Boulogne, France
{dagger}Laboratoires Merrell Dow SA Levallois, France

Received 19 October 1992; revised 10 August 1993; .

Coresspondence: Dr Guillaume Jondeau. Service de Cardiologie, Hôpital A. Paré, 9 Av Charles de Gaulle, 92100 Boulogne, France

Abstract

We performed a double-blind, placebo-controlled study to determine whether oral enoximone would aid weaning dobutamine-dependent patients.

Twenty-four patients 64±10 years, with an echocardiographic ejection fraction of 0·20 ± 0·06, and receiving maximal therapy were studied. After failure of dobutamine weaning, a dobutamine infusion was set up at 10 µg. kg–1. min–1 for 48 h. Oral enoximone (100 mg t.i.d.) or placebo was added from D0 for the next 28 days, while the dobutamine dosage was progressively decreased after D4 and eventually stopped at D7. The patients were then followed-up for 21 days (i.e. until enoximone administration had continued for 28 days).

In the placebo group, two patients suffered a relapse of congestive heart failure (CHF) before D4 six patients withdrew during dobutamine tapering (five with a relapse of CHF and one with septic shock) and two during follow-up (one with a relapse of CHF and one with sustained ventricular tachycardia). In the enoximone group, three patients withdrew during dobutamine tapering (two with a relapse of CHF, one with a cutaneous rash). Four patients on placebo and nine receiving enoximone could be weaned from dobutamine, P<0y05. Echocardiographic LV ejection fraction significantly increased and Doppler-derived indexes of systolic function tended to increase when enoximone but not placebo was associated with dobutamine.

Oral enoximone might be helpful in weaning patients with end-stage congestive heart failure from i.v. dobutamine.

Key Words: Enoximone • dobutamine • congestive heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.